An overview on various analytical methods for estimation of safinamide from its bulk and pharmaceutical dosage form

https://doi.org/10.54037/WJPS.2021.91108

Abstract

Safinamide mesylate (SAF)(S1), also known as (S)-2-(4-((3-Fluorobenzyl) oxy) benzyl) amino) propanamide methane sulfonate, is a medication that was recently created to treat Parkinson's disease (PD). Safinamide is an MAO-B inhibitor that is used to supplement levodopa/carbidopa in the treatment of Parkinson's disease during "off" episodes. According to the literature, High Performance Thin Layer Chromatography (HPTLC), Bioanalytical Method Development of Safinamide by UPLC-MS/MS, and RP-HPLC Stability Indicating Assay Method Development and Validation were used to monitor safinamide. Selectivity, precision, linearity, and accuracy were all used to validate the authors' proposed technique. All the validation parameters were within acceptable limits. There have been numerous ways for determining safinamide.